Literature DB >> 32501632

Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection.

Yun-Fan Sun1,2, Peng-Xiang Wang1,2, Jian-Wen Cheng1,2, Zi-Jun Gong1,2, Ao Huang1,2, Kai-Qian Zhou1,2, Bo Hu1,2, Ping-Ting Gao1,2, Ya Cao3,4, Shuang-Jian Qiu1,2, Jian Zhou1,2,5, Jia Fan1,2,5, Wei Guo6, Xin-Rong Yang1,2.   

Abstract

BACKGROUND: Postoperative extrahepatic metastases (EHM) contribute to a grim outcome in patients with hepatocellular carcinoma (HCC) who are undergoing curative surgical resection. The current study investigated the clinical value of circulating tumor cells (CTCs) in predicting EHM after curative surgery.
METHODS: A total of 197 patients with HCC who were undergoing curative surgical resection were assigned to a retrospective training cohort (144 patients) or a prospective validation cohort (53 patients). The CELLSEARCH system was used for the detection of CTCs prior to surgical resection and 1 month thereafter. The cutoff value of CTCs was estimated using receiver operating characteristic analysis. Bonferroni correction was applied for multiple testing in a Cox proportional hazards regression model.
RESULTS: In the training cohort, EHM was found to be associated with a higher postoperative CTC burden compared with no EHM (mean: 4.33 vs 0.52; P < .001). Receiver operating characteristic analysis demonstrated a postoperative CTC count ≥3 as the optimal cutoff value for the prediction of EHM. Patients with a postoperative CTC count ≥3 experienced a higher EHM risk (56.3% vs 5.5%) and a shorter median overall survival (31.25 months vs not reached) (all P < .001). The prognostic significance of a postoperative CTC count ≥3 also applied to patient subgroups with a low EHM risk, such as those with an α-fetoprotein level ≤400 ng/mL, absence of vascular invasion, well differentiation, and early tumor stage, and its predictive value was retained in patients with a continuous normal α-fetoprotein level during postoperative follow-up (all P < .05). The results were confirmed in the validation cohort.
CONCLUSIONS: A postoperative CTC count ≥3 appears to be a surrogate marker for the prediction of EHM after curative surgical resection of HCC. More careful surveillance should be recommended to patients with a high CTC load to ensure the greater possibility of early interventions for postoperative EHM.
© 2020 American Cancer Society.

Entities:  

Keywords:  circulating tumor cells (CTCs); early predictor; extrahepatic metastases; hepatocellular carcinoma (HCC); postoperative

Mesh:

Year:  2020        PMID: 32501632     DOI: 10.1002/cncy.22304

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  8 in total

1.  An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming.

Authors:  Hua-Hua Liu; Yang Xu; Cao-Jie Li; Shu-Jung Hsu; Xia-Hui Lin; Rui Zhang; Jie Chen; Jun Chen; Dong-Mei Gao; Jie-Feng Cui; Xin-Rong Yang; Zheng-Gang Ren; Rong-Xin Chen
Journal:  Mol Ther       Date:  2022-03-28       Impact factor: 12.910

Review 2.  Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal.

Authors:  María Lola Espejo-Cruz; Sandra González-Rubio; Javier Zamora-Olaya; Víctor Amado-Torres; Rafael Alejandre; Marina Sánchez-Frías; Rubén Ciria; Manuel De la Mata; Manuel Rodríguez-Perálvarez; Gustavo Ferrín
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

Review 3.  Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma.

Authors:  Huang Ao; Zhang Xin; Zhou Jian
Journal:  Biomark Res       Date:  2021-12-20

Review 4.  Circulating tumor cells: biology and clinical significance.

Authors:  Danfeng Lin; Lesang Shen; Meng Luo; Kun Zhang; Jinfan Li; Qi Yang; Fangfang Zhu; Dan Zhou; Shu Zheng; Yiding Chen; Jiaojiao Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-11-22

Review 5.  Clinical applications of circulating tumor cells in hepatocellular carcinoma.

Authors:  Yinggang Hua; Jingqing Dong; Jinsong Hong; Bailin Wang; Yong Yan; Zhiming Li
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

Review 6.  Detection of circulating tumor cells: opportunities and challenges.

Authors:  Siwei Ju; Cong Chen; Jiahang Zhang; Lin Xu; Xun Zhang; Zhaoqing Li; Yongxia Chen; Jichun Zhou; Feiyang Ji; Linbo Wang
Journal:  Biomark Res       Date:  2022-08-13

Review 7.  Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.

Authors:  Maria Pallozzi; Natalia Di Tommaso; Valeria Maccauro; Francesco Santopaolo; Antonio Gasbarrini; Francesca Romana Ponziani; Maurizio Pompili
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

8.  Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation.

Authors:  Víctor Amado; Sandra González-Rubio; Javier Zamora; Rafael Alejandre; María Lola Espejo-Cruz; Clara Linares; Marina Sánchez-Frías; Gema García-Jurado; José Luis Montero; Rubén Ciria; Manuel Rodríguez-Perálvarez; Gustavo Ferrín; Manuel De la Mata
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.